U.S. Markets closed

Why A Highly Rated Biotech With A 54% Gain This Year Is Being Gutted

ALLISON GATLIN
Why A Highly Rated Biotech With A 54% Gain This Year Is Being Gutted

Ionis Pharmaceuticals was slammed Wednesday on competitive gene-therapy data from Novartis' AveXis unit and amid apparently disappointing comments from Roche in Huntington's disease.